New Key Statistics Module, Z-Score and F-Score
NAS:NAMS Key Ratios
| Market Cap $ M | 1,752.92 |
| Enterprise Value $ M | 1,304.21 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 5.67 |
| Price/Sales | 115.35 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 14.00 |
| EPS (TTM) $ | -2.15 |
| Beneish M-Score | -1.46 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -7.37 |
| EV-to-EBITDA | -7.37 |
| PEG | -- |
| Shares Outstanding M | 89.99 |
| Net Margin (%) | -1,255.76 |
| Operating Margin % | -1,242.76 |
| Pre-tax Margin (%) | -1,255.57 |
| Quick Ratio | 6.95 |
| Current Ratio | 6.95 |
| ROA % (ttm) | -39.69 |
| ROE % (ttm) | -45.09 |
| ROIC % (ttm) | -341.61 |
| Dividend Yield % | -- |
| Altman Z-Score | 16.43 |
NAMS Number of Guru Trades
NAMS Volume of Guru Trades
Gurus Latest Trades with NAS:NAMS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:NAMS is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NewAmsterdam Pharma Co NV Insider Transactions
No Available Data
News about NAS:NAMS
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers